文献速递肾小球疾病

克隆导向策略或改善单克隆免疫球蛋白沉积性增生性肾小球肾炎诊治

A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits.
PubMed 文献 · Kidney Int · 2018-05-11

本文为19例单克隆免疫球蛋白沉积性增生性肾小球肾炎(PGNMID)患者的回顾性病例系列,采用较统一的克隆导向治疗策略。循环副蛋白检出率为37%,总体克隆检出率为32%;16例接受治疗者总体肾脏缓解率为88%,初始治疗完全肾脏缓解率为38%,末次随访均未进展至终末期肾病。

要点

  • PGNMID患者克隆检出率有限,循环副蛋白检出率37%、总体克隆检出率32%。
  • 克隆导向治疗后总体肾脏缓解率88%,完全肾脏缓解率38%。
  • 中位随访693天时全部患者均未进展至终末期肾病,治疗耐受良好。

核心结论

  • 克隆导向策略可能为PGNMID带来新的靶向治疗思路,并显著改善患者结局。

研究设计与样本

  • 回顾性病例系列,纳入19例PGNMID患者,采用较统一的克隆导向治疗策略。
  • 其中16例接受了治疗。

主要发现

  • 循环副蛋白检出率为37%,总体克隆检出率为32%。
  • 16例接受治疗者的总体肾脏缓解率为88%,初始治疗完全肾脏缓解率为38%。
  • 完全肾脏缓解定义为蛋白尿降至0.5 gm/24小时以下。
  • 全部患者在末次随访时均未进展至终末期肾病,中位随访为诊断后693天,治疗耐受良好。

临床怎么用

  • 对PGNMID患者应尽量寻找并针对潜在克隆进行治疗;无检出克隆者可经验性针对推测克隆治疗。

局限性

  • 为回顾性病例系列,样本量19例,证据强度有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The optimal treatment for the monoclonal gammopathies of renal significance is not known, but there is consensus among experts that treatment should be specific for the underlying clone. The majority of patients with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) do not have an identifiable clone, and prior studies have found poor renal outcomes for patients with PGNMID treated with a variety of regimens. Here we present a retrospective case series of 19 patients with PGNMID with a more uniform, clone-directed approach. A circulating paraprotein was detected in 37% of patients, and the overall clone detection rate was 32%. Treatment was directed at the underlying clone or, for patients without a detectable clone, empirically prescribed to target the hypothesized underlying clone. Of the 16 patients who underwent treatment, the overall renal response rate was 88%, and 38% of patients experienced complete renal response (proteinuria reduction to under 0.5 gm/24 hours) with initial treatment. All patients were End Stage Renal Disease-free at last follow-up (median 693 days after diagnosis), and treatment was well tolerated. Thus, a clone-directed approach may lead to novel, targeted treatment strategies that could significantly improve outcomes for patients with PGNMID.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Gumber R, Cohen JB, Palmer MB, et al. A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Kidney Int. 2018. PMID: 29759418. doi:10.1016/j.kint.2018.02.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。